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Abstract
Patients with an inborn error of metabolism (IEM) are deficient of an enzyme involved in metabolism, and as a consequence
metabolism reprograms itself to reach a new steady state. This new steady state underlies the clinical phenotype associated with
the deficiency. Hence, we need to know the flux of metabolites through the different metabolic pathways in this new steady state
of the reprogrammed metabolism. Stable isotope technology is best suited to study this. In this review the progress made in
characterizing the altered metabolism will be presented. Studies done in patients to estimate the residual flux through the
metabolic pathway affected by enzyme deficiencies will be discussed. After this, studies done inmodel systems will be reviewed.
The focus will be on glycogen storage disease type I, medium-chain acyl-CoA dehydrogenase deficiency, propionic and
methylmalonic aciduria, urea cycle defects, phenylketonuria, and combined D,L-2-hydroxyglutaric aciduria. Finally, new de-
velopments are discussed, which allow the tracing of metabolic reprogramming in IEM on a genome-wide scale. In conclusion,
the outlook for flux analysis of metabolic derangement in IEMs looks promising.
Introduction
Inborn errors of metabolism (IEMs) form a large class of ge-
netic diseases involving congenital disorders of metabolism.
The majority are due to defects of single genes that code for
enzymes that facilitate conversion of substrates into products.
Although individual IEMs are rare, collectively they represent
a large and diverse group of diseases. The majority of IEMs
has a prevalence of less than 10 per 100,000 births with a total
prevalence of all IEMs reaching 40 per 100,000 births, al-
though the prevalence varies considerably worldwide based
on the racial and ethnic composition of the population. From a
societal point of view IEMs are an important burden of the
medical care systems in Western countries where the most
common communicable diseases are eradicated.
Although several approaches are used to treat patients with
an IEM, they all have the common goal to overcome the
biochemical aberrations caused by the primary enzyme defect.
Therefore, understanding of the molecular and biochemical
etiologies of the many IEMs is essential for successful treat-
ment of these patients. Flux analyses by stable isotope meth-
odology forms an important modality in the study of IEMs.
When an enzyme is deficient, metabolism seeks a new
steady state, away from its physiological homeostasis. A
new balance of fluxes associated with the consumption and
production of metabolites characterizes the new steady state.
A flux is the actual flow of metabolites through a metabolic
pathway and is determined by both the rate of supply of sub-
strates and the capacity of that pathway to convert them into
products. Hence, neither changes in concentrations of inter-
mediates nor changes in enzyme concentrations and/or activ-
ities of the reprogrammed metabolism separately hold infor-
mation on the changes of the distribution of fluxes. The ques-
tion arises of how to measure these changes. This review
focuses mainly on studies applying stable isotope technology
with mass spectrometric detection of mass isotopomer distri-
butions (MID) of metabolites after separation by chromatog-
raphy. In the next section, a short overview of the relevant
stable isotope technology will be given followed by a discus-
sion of the experimental studies over the last decades of a
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selected group of IEM; glycogen storage disease type I (GSD
I), medium-chain acyl-CoA dehydrogenase (MCAD) defi-
ciency, propionic aciduria (PA) and methylmalonic aciduria
(MMA), urea cycle defects (UCD), phenylketonuria (PKU)
and combined D,L-2-hydroxyglutaric aciduria. An earlier dis-
cussion of the application of stable isotopes in IEM can be
found in Eur J Pediatr 156 Supplement 1 (1997).
Methods of stable isotope tracer technology
used in studies of flux analysis in IEM
Isotope dilution of an exogenous infused metabolite
Two applications of stable isotope tracer studies have been
used most often in the field of inborn errors of metabolism,
isotope dilution of an exogenous infused labeled metabolite
(this section) and isotope dilution of an endogenous produced
metabolite (next section). For our discussion of the application
of stable isotopes two assumptions will be essential: (i) me-
tabolism of labeled tracer and unlabeled tracee is indistin-
guishable and (ii) metabolism of tracee and tracer is at steady
state. At steady-state no changes occur in the concentrations of
tracer and tracee. Hence, rate equations reduce to algebraic
equations, which can be solved easily. Moreover, at steady
state the rate of production of the metabolite of interest equals
the rate of its consumption. When the aim of a study is to
estimate the rate of appearance of a metabolite (Ra) in vivo
in animals or humans, an experiment can be performed in
which a solution of an isotopically labeled compound
(tracer) is intravenously infused and the dilution of the tracer
by the tracee is measured in the circulation. To keep the dis-
cussion clear, the estimation of the rate of appearance of glu-
cose into the systemic circulation will serve as an illustration.
A solution of stable isotope labeled glucose is continuously
infused intravenously at a rate Vinf into the systemic circula-
tion of the animal or human. Suppose glucose is labeled at all
six carbon atoms with 13C (a.k.a. uniformly labeled glucose,
[U-13C]-glucose). At different time points blood samples are
drawn and after work-up of the samples the MID of glucose at
the various time points is measured by gas chromatography
coupled to mass spectrometry. Only the time points at isotopic
steady-state will be used. Next the measured intensities are
normalized to the sum of the intensities of all mass
isotopomers comprising the measured MID and the relative
contributions are calculated for glucose molecules labeled
with no 13C atom (m0), 1
13C atom (m1), 2
13C atoms (m2) till
6 13C atoms (m6) with ∑6i¼1mi ¼ 1. Carbon is naturally
enrichedwith 13C (about 1.07% (Meija et al 2016)); therefore,
the recorded MID contains glucose molecules labeled by nat-
ural enrichment and by the infused [U-13C]-glucose. After
correction of the recorded MID for natural enrichment of
13C (Midani et al 2017) the corrected MID (M0 – M6 with
∑6i¼1Mi ¼ 1 ) is solely determined by the dilution of labeled
glucose (Mglc6 (infuse)) by unlabeled glucose entering the sys-
temic circulation. Since measurements at steady-state are
used, Ra can be calculated in two steps; (i) the total rate of
appearance (Ra(tot)) of glucose is calculated by Eq.1 and (ii)
Ra(tot) is corrected for the rate of infusion of labeled glucose
(Vinf) according to Eq.2 to obtain the rate of appearance (Ra)
of unlabeled glucose:
Rglca totð Þ ¼
Mglc6 infuseð Þ
Mglc6 bloodð Þ




is the dilution of the tracer [U-13C]-glucose by
the tracee unlabeled glucose and
Rglca ¼ Rglca totð Þ‐Vinf ð2Þ
It should be realized that the calculated rate of appearance
represents the flux through the studied pool (in our case, glu-
cose in the systemic circulation) at the steady state studied and
does not give information on the total capacity of the meta-
bolic pathway, nor on the flux at a different steady state.
Isotope dilution of an endogenously produced
metabolite
Let us now consider the appearance of glucose in the circula-
tion during fasting with contributions of glycogenolysis and
gluconeogenesis.When one of these processes can be estimat-
ed independent from the other, we gain information on how
the appearance of glucose is determined by these two process-
es. To this purpose Hellerstein and coworkers developed an
approach to estimate the rate of gluconeogenesis by a method
they named mass isotopomer distribution analysis (MIDA)
(Hellerstein and Neese 1992). Kelleher and coworkers devel-
oped a similar approach, which they named isotopomer spec-
tral analysis (Kelleher and Masterson 1992; Kelleher and
Nickol 2015; Tredwell and Keun 2015). During gluconeogen-
esis glucose is made from fructose-1,6-bisphosphate (Frc-1,6-
P2), which is the product of the condensation of
dihydroxyacetonphosphate (DHAP) and glyceraldehyde-3-
phosphate (GA3P) by aldolase (Fig. 1). In vivo labeling of
DHAP and GA3P is accomplished by intravenous infusion of
a solution containing [2-13C]-glycerol and this will never result
in complete labeling of the intracellular pools of DHAP and
GA3P. Therefore, unlabeled DHAP and GA3P will always be
present. Hence, condensation of labeled and unlabeled DHAP
and GA3P randomly selected by aldolase will result in a mix-
ture of labeled and unlabeled Frc-1,6-P2 and subsequently of
labeled and unlabeled gluconeogenic glucose. When unlabeled
DHAP condenses with unlabeled GA3P, it results in unlabeled
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M0 Frc-1,6-P2, unlabeled DHAP with labeled [2-
13C]-GA3P
results in single labeled M1 Frc-1,6-P2, similar to the conden-
sation of labeled [2-13C]-DHAP with unlabeled GA3P and la-
beled [2-13C]-DHAPwith labeled [2-13C]-GA3P results in dou-
ble labeledM2 Frc-1,6-P2. The higher the enrichment of DHAP
and GA3P, the higher will be the contribution of M2 Frc-1,6-P2
(compare Fig. 1a with Fig. 1b). When this set of unlabeled and
labeled Frc-1,6-P2 is converted into glucose, it will be diluted
by unlabeled glucose-6-phosphate (G6P) released by glycogen-
olysis. Thus, unlabeled glucose not only arises from gluconeo-
genesis because of the incomplete labeling of the monomeric
pool of triose-phosphates but also from glycogenolysis. To cor-
rect for the synthesis of unlabeled glucose by gluconeogenesis,
Hellerstein and coworkers treated gluconeogenesis as a kind of
‘polymerization’ reaction, with glucose as a ‘dimer’ of the
monomer triose-phosphate (Hellerstein and Neese 1992) (Fig.
1c). The MID of labeled glucose can then be described by a
frequency distribution of two monomers, labeled and unlabeled
triose-phosphate. The mass isotopomers M1 and M2 of glucose
are used to calculate the triose-phosphate enrichment. Next, this
calculated triose-phosphate enrichment is used to calculate the
‘true’ MID (M0-M2) of newly synthesized glucose. This ‘true’
MID (‘tracer’) is compared to the measured MID of glucose
(‘tracee’) in the circulation to calculate the degree of dilution of
gluconeogenic glucose. In this way, Eq. 1 can be applied to
calculate the rate of gluconeogenesis Vgng. M
glc
6 infuseð Þ is re-
placed by Mglc1 gng glcð Þ. In general the calculated fraction of
M1 gluconeogenic glucose (M
glc
1 gng glcð Þ ) can be chosen be-
cause it shows the highest contribution to the MID of
gluconeogenic glucose (unpublished observations). Mglc6
bloodð Þ is replaced by Mglc1 bloodð Þ, the measured fraction of
M1 glucose in the circulation and Vinf is replaced by Vgng, the
parameter to be calculated. Ra, the rate of glucose appearance
Fig. 1 Schematic representation of ‘dimerization’ of triose-phosphates in
the gluconeogenic synthesis of glucose. a Dimerization of triose-
phosphates at low enrichment of triose-phosphate pool; b Dimerization
of triose-phosphates at high enrichment of triose-phosphate pool; c The
equations used to calculate the triose-phosphate enrichment from the
observed MID of glucose and the ‘true’ MID of newly synthesized
glucose; d The theoretical MID at different enrichments of the triose-
phosphate pool. Blue circles represent unlabeled triose-phosphate
molecules, red circles represent labeled triose-phosphate molecules, and
connected circles represent glucose molecules, with all blue M0, single
red M1, and double red M2 mass isotopomers
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into the systemic circulation is measured separately by isotope
dilution of [U-13C]-glucose. In this way the ‘true’ Vgng can be
calculated. By subtraction of Vgng fromRa of glucose the rate of
glycogenolysis is obtained.
Labeling of the triose-phosphate pool can also be achieved
by infusing appreciable amounts of [U-13C]-glucose, which
results in labeling of the triose-phosphate pool. Extensive me-
tabolism of glucose by glycolysis, TCA cycle, and gluconeo-
genesis gives rise to M0 – M3 triose-phosphate and M0 – M6
glucose. This phenomenon is referred to as ‘scrambling’ of the
glucose label.
MIDA can also be used to estimate de novo lipogenesis
in vivo. During de novo synthesis of palmitate, FASN concat-
enates eight acetate molecules. Palmitate can thus be consid-
ered an ‘octamer’ of the monomer acetate. In in vivo experi-
ments infusion of [2-13C]-acetate labels the intracellular pool
of acetate used for lipogenesis only moderately, and labeled
and unlabeled acetate will be incorporated into palmitate.
Hence, newly synthesized palmitate consists of a mixture of
labeled and unlabeled molecules. Unlabeled palmitate is a
mixture from preexisting and lipogenic palmitate. Similar to
the case of glucose, these two sources of unlabeled palmitate
can be distinguished by MIDA. The MID of newly synthe-
sized palmitate can be described by a frequency distribution of
an octamer with two monomers, labeled and unlabeled ace-
tate. The enrichment of acetate is calculated from the mea-
sured mass isotopomers M1-M8 of labeled palmitic acid.
Next, the ‘true’ MID of newly synthesized palmitate (M0 –
M8) is calculated. The measuredMID (M0 –M8) of palmitate,
in for instance VLDL, reflects the dilution of the newly syn-
thesized palmitate by existing palmitate. The rate of de novo
lipogenesis is estimated with Eq. 1, when the rate of appear-
ance of palmitate into the studied pool is accessible for mea-
surements. Otherwise, only the fraction of newly synthesized
palmitate can be estimated. Oosterveer et al (2009) extended
the method to calculate the degree of chain-elongation of pal-
mitate into stearate and oleate.
In summary, in the case of a ‘polymerization’ reaction, a
decrease in label incorporation into products can be due to (i) a
decrease in enrichment of the monomers without a change in
dilution of the newly synthesized product or (ii) a greater
dilution of the newly synthesized product but with the same
enrichment of the monomers. In the first case the MID of the
labeled product will shift to lower mass isotopomers, in the
latter case the relationship between the 13C–labeled product
mass isotopomers (M1-Mi) remains the same but the abun-
dances of the mass isotopomers of the labeled product (M1-
Mi) decrease compared to the unlabeled product (M0).
Oral loading tests
Oral loading tests are used to evaluate the degree of impair-
ment of metabolism due to the deficiency of a particular
enzyme in a non-invasive manner. In an oral loading test a
labeled precursor is given and the degree of transfer of the
label to a metabolic end-product is measured. In a breath test,
an oral bolus of a 13C–labeled precursor is given and the
enrichment of 13CO2 is measured. It is assumed that in this
way the rate of oxidation of the substrate can be estimated.
Similarly, when an oral bolus of 15NH4CO3 is given and the
enrichment of [15N]-urea is measured it is assumed that the
rate of urea synthesis in vivo can be estimated. Although sim-
ple to perform, these tests suffer from serious drawbacks. Very
appreciable variation in test outcome is observed due to un-
known dilution of the labeled precursor by metabolism in the
studied subjects and by bacterial metabolism in the intestinal
tract, unknown dilution of the end product, particularly when
13CO2 is used (Veeneman et al 2005), incomplete recovery of
the isotope given and poor repeatability of tests (Kalivianakis
et al 1997). It is for these reasons that we concluded that oral
loading tests with label transfer into metabolic end products
are of limited use for the quantitative assessment of the flux
through the metabolic pathway under study (Reijngoud and
Verkade 2017). Therefore, the oral loading test will not be
discussed.
Irrespective of this conclusion, an interesting approach
might be the use of [1-13C]-acetate to measure the residual
activity of the urea cycle in patients with a urea cycle defect
(Yudkoff et al 1998). Besides the appearance of 13C in urea,
these authors also measured the enrichment of 13CO2 in ex-
haled air. When the changes of the enrichment of 13C in urea
were corrected for the changes of the enrichment of breath
13CO2, the authors were able to calculate a urea cycle activity
in a control subject not different from the values obtained by a
primed-continuous infusion protocol (see Urea cycle defects
section for discussion).
Experimental studies
Glycogen storage disease type I
Residual glucose production in patients with GSD Ia in vivo
The measurement of glucose production in patients GSD I
(MIM# 607008) has been pursued over many decades (see
Fig. 2 for a timeline) by isotope dilution of various stable
isotope labeled glucose molecules. In GSD I the conversion
of glucose-6-phosphate (G6P) into glucose by the glucose-6-
phosphatase complex (G6Pase) (EC# 1.3.8.7) is deficient.
Hence, G6P generated by gluconeogenesis and glycogenoly-
sis cannot be converted into glucose. This prevents
gluconeogenic organs, mainly liver, to produce glucose when
the prandial release of glucose by the intestine dwindles down
and finally stops. One expects that in these patients no endog-
enous glucose production could exist. Quite to the contrary,
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several studies applying dilution of infused stable isotope la-
beled glucose have shown that in these patients an appreciable
glucose production exists. The measurement of the rate of
appearance of glucose in GSD Ia patients started in 1984 with
a study by Tsalikian et al (1984). Five children with GSD I
were infused with [6,6-2H2]-glucose intravenously and the
isotope dilution of [6,6-2H2]-glucose in blood samples drawn
at isotopic steady state was measured. The endogenous glu-
cose production equaled 21.4 ± 0.2 μmol.kg−1.min−1, consid-
erably less than in unaffec ted chi ldren (34 .6 ±
0.2 μmol.kg−1.min−1), but still appreciable (~60% of control).
They also measured the endogenous glucose production while
the infusion rate of exogenous unlabeled glucose was in-
creased stepwise. At the highest exogenous glucose infusion
rate of 33.3 μmol.kg−1.min−1 endogenous glucose production
could still bemeasured, although the rate was decreased to 7.1
± 0.4 μmol.kg−1.min−1. Comparable observations were made
by Wengler et al (2007) and Huidekoper et al (Huidekoper
et al 2010). Kalderon and coworkers (Kalderon et al 1989a,
Kalderon et al 1988, Kalderon et al 1989b) studied glucose
production with [13C6]-glucose and measure isotope dilution
and ‘scrambling’ of 13C–labeling in glucose by NMR. They
also showed that GSD I patients produced glucose, and that
the rate was lower than in healthy subjects. However, in con-
trast to healthy subjects, essentially no ‘scrambling’ of
[U-13C]-glucose was observed. Jones et al (2009) measured
gluconeogenesis and anaplerosis of the TCA cycle in five fed
healthy subjects and five GSD Ia patients on cornstarch
therapy. All subjects received a dose of acetaminophen,
phenylbutyrate, and [U-13C]-glycerol. Blood and urine sam-
ples were collected and label distributions were measured by
NMR of glucose in plasma and of the glucuronate residue of
acetaminophen glucoronate, reflecting G6P labeling, and of
the glutamine residue in N-phenylacetylglutamine, reflecting
2-ketoglutarate labeling. In healthy subjects 35 ± 14% of plas-
ma glucose originated from hepatic G6P, while in patients no
detectable contribution of G6P to plasma glucose was ob-
served. Moreover, in GSD1a patients, labeling pattern in the
glutamine residue of N-phenylacetylglutamine pointed to a
redirection of the fluxes through the Krebs cycle to dispose
of carbon normally used in gluconeogenesis to lactate
production.
Collectively, these studies proved the existence of an en-
dogenous glucose production in children with GSD I that even
responded to exogenous glucose infusion. A process funda-
mentally different from gluconeogenesis, however, sustains
the endogenous glucose production in GSD I patients.
Moreover, metabolism of pyruvate was reprogrammed with
a shift from anaplerosis to lactate production.
Glucose metabolism in animal models of GSD Ia and Ib
Tsalikian et al (1984) hypothesized that glucose production in
GSD Ia could be driven by the glucosidase activity of
debranching enzyme or lysosomal α-glucosidase after au-
tophagy of glycogen (a.k.a. glycophagy, (Jiang et al 2011)).
Fig. 2 Timeline of measurements
of endogenous glucose
production in GSD I patients and
development of model systems in
mice. The references mentioned
are (Powell et al 1981), (Tsalikian
et al 1984), (Kalderon et al
1989a), (Rother and Schwenk
1995), (Lei et al 1996), (van Dijk
et al 2001), (Weghuber et al
2007), (Jones et al 2009),
(Huidekoper et al 2010), (Mutel
et al 2011) (Hijmans et al 2017)
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These hypotheses are difficult to reconcile with the intracellu-
lar presence of glucokinase/hexokinase, which will most like-
ly rapidly convert intracellularly released glucose into G6P.
The question arises, however, of whether hepatic metabolism
of G6P in GSD I is still comparable to that in healthy controls.
Van Dijk et al (2001) published a series of experiments on
glucose metabolism in rats acutely treated with S4048, an
inhibitor of G6P transporter, mimicking GSD Ib (Fig. 3).
They used the isotopic model of Hellerstein (Hellerstein et al
1997) to study the rearrangement of the flux distribution
around G6P during an infusion of S4048 (Fig. 3a).
Conscious and freely moving rats were infused with a multi
tracer solution of [U-13C]-glucose, [2-13C]-glycerol, [1-2H]-
galactose, acetaminophen, and when necessary S4048.
During infusion blood samples were drawn and timed urine
samples were collected. Label distributions were measured in
glucose in plasma and the glucuronide moiety of acetamino-
phen glucuronic acid in urine. The label distribution in the
glucuronide moiety of acetaminophen-glucuronate reflects
the label distribution in the glucose moiety of UDP-glucose,
which is in rapid equilibrium with G6P. In this isotope model
the following fluxes are measured: (i) whole body glucose
production, by dilution of infused [U-13C]-glucose, (ii) the
glucokinase flux by the appearance of the label of [U-13C]-
glucose in the glucuronide moiety of acetaminophen-
glucuronate, (iii) gluconeogenesis, by [2-13C]-glycerol incor-
poration into glucose and glucose moiety of acetaminophen
glucuronic acid, (iv) glycogen synthesis, by dilution of [1-2H]-
galactose in the glucuronide moiety of acetaminophen glucu-
ronic acid, (v) the G6Pase flux by the appearance of label from
[1-2H]-galactose in glucose in plasma. Assuming flux balance
at G6P all fluxes in this model can be calculated. At an infu-
sion rate of S4048 of 0.53 ± 0.03 mg.kg−1.min−1 the G6Pase
flux decreased by 50% (Fig. 3b). Intracellular concentration of
G6P increased from 0.5 ± 0.1 to 2.7 ± 0.3 μmol.(g liver wet
weight)−1. The rate of glycogenesis increased as expected in
view of the increased G6P concentrations. Quite strikingly,
glucokinase flux was almost abolished. It was hypothesized
that the high intracellular concentrations of G6P increased
fructose-6-phosphate which inhibited glucokinase activity by
the stimulation of the formation of the inhibitory complex of
glucokinase and glucokinase regulatory protein (see (Lenzen
2014) for a review). Hence, cytosolic glucose, released by
debranching enzyme or lysosomal α-glucosidase could es-
cape phosphorylation and be transported into the systemic
circulation.
The generation of mice with a liver specific G6Pc knockout
offers new possibilities to study metabolic mechanisms more
closely underlying the endogenous glucose production (Mutel
et al 2011). Very recently, Hijmans et al (2017) applied the
above described model of hepatic glucose metabolism to
study glucose metabolism in these mice (Fig. 4a). They
showed by in vivo analysis of hepatic glucose metabolism in
these mice that the hepatic glucokinase flux was decreased by
95% in L-G6pc−/− mice (Fig. 4b). Glycogen synthase flux
and phosphorylase flux were increased, resulting in an almost
tenfold increase in cycling of the glucose moiety in UDP-
glucose (Fig. 4b-e) in L-G6pc−/− mice. As a consequence,
this gave rise to a tenfold increase of the release of free glucose
via glycogen debranching. Furthermore, the authors showed
that pharmacological inhibition of α-glucosidase activity by
deoxynojirimycin almost abolished the residual glucose pro-
duction in isolated G6pc-deficient primary hepatocytes. In
conclusion, glucosidase activity sustains the glucose produc-
tion in GSD Ia patients. Glucose phosphorylation is strongly
suppressed. When patients with GSD Ia were treated with a
Fig. 3 Effects of S4048 treatment in fasted rats on the fluxes through
hepatic carbohydrate pathways. a Schematic representation of the major
metabolic pathways considered in the model of hepatic carbohydrate
metabolism of Hellerstein et al (1997). The pathways included are:
gluconeogenesis (de novo synthesis of G6P from pyruvate);
glycogenolysis; G6Pase; glucosekinase; and glycogenesis. Infused
labeled metabolites are presented in blue, sampling sites and the
sampled compounds are presented in red. S4048 inhibits G6P to glucose
pathway. b The values obtained for the fluxes through the pathways
depicted in (a) in vehicle-treated (gray bars) and S4048 treated rats
(black bars). (n = 3) Source: (van Dijk et al 2001), reproduced with
permission from the American Society of Biochemistry and Molecular
Biology
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glucose infusion or continuous glucose supply from corn-
starch, glucose production decreased (Tsalikian et al).
Hijmans et al (2017) proposed that increased exogenous glu-
cose supplymight reactivate glucokinase. Subsequently, intra-
cellular released glucose by glucosidase activity will be phos-
phorylated and glucose appearance in the circulation will
decrease.
Lipid metabolism in patients with GSD Ia in vivo
In GSD I patients lipid metabolism is severely perturbed. GSD
Ia patients suffer from a combined hypertriglyceridemia and
hypercholesterolemia. In a preliminary study de novo lipogen-
esis and cholesterol synthesis were measured in two GSD Ia
patients by the infusion of [2-13C]-acetate, the measurement of
the incorporation of 13C label in palmitate in VLDL and the
analysis of the data by MIDA (Bandsma et al 2002). Both
rates were strongly elevated. Later Bandsma et al (2008) ex-
tended these studies and included the rate of VLDL synthesis
by the incorporation of infused [1-13C]-valine into apoB100.
The results showed de novo lipogenesis was enhanced in GSD
Ia patients confirming earlier results. The results of the incor-
poration of [1-13C]-valine into apoB100 showed that the rate
of VLDL synthesis was not affected. In view of these results
the authors hypothesized that lipolysis in GSD Ia patients
must be impaired.
Lipid metabolism in animal model of GSD Ib
These results of lipid metabolism in GSD I patients were par-
tially reproduced in rats treated with S4048 (Bandsma et al
2001). Acute inhibition of the G6P translocator led to a tenfold
increase in de novo lipogenesis, albeit cholesterol synthesis
remained unaffected. Levels of triglyceride in blood rose al-
most twofold during an 8 h infusion of rats with S4048, while
VLDL production was not affected. Apparently, VLDL lipol-
ysis must have been impaired. These metabolic changes were
accompanied by increased expression of the genes encoding
FASN and ACAT1. The enhanced expression turned out to be
driven by ChREBP, a nutrient sensing-transcription factor ac-
tivated by G6P, among other sugar-phosphates (Richards et al
2017). When whole body ChREBP knockout mice were treat-
ed with S4048 the increase in expression of the genes
encoding FASN and ACAT1 was abolished (Grefhorst et al
2010).
In conclusion, metabolic reprogramming in GSD I resulted
in an endogenous glucose production by an alternative path-
way mediated by the glucosidase activity of glycogen
debranching enzyme and/or lysosomal glycogen degradation.
Fig. 4 Hepatic carbohydrate metabolism in mice with a liver-specific
knock-out of G6Pc. (a) Schematic representation of the model of
hepatic carbohydrate metabolism. The red arrow indicates the liver-
specific knockout of G6Pc. see legend of Fig. 3a for explanation.
Figures 3(b), (c), (d), (e) show the boxplots of the flux through
glucokinase, UDP-glucose cycling, glycogen synthase, and glycogen
phosphorylase, respectively, with L-G6Pc+/+ mice (white boxes) (n = 6)
and L-G6Pc−/− mice (black boxes) (n = 6). Values are depicted as
boxplots with middle line: median, box: 25th to 75th percentiles and
whiskers: 5th and 95th percentiles for n = 6 per group. *P < 0,05.
Source: (Hijmans et al 2017), reproduced with permission from the
American Association of the Study of Liver Diseases
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Phosphorylation of glucose was almost abolished. De novo
lipogenesis and cholesterol synthesis were increased. VLDL
production was not affected. Lipid levels in blood were in-
creased, which pointed to impaired lipolysis. These changes
appeared to be brought about by an active and regulated pro-
cess mediated in part by G6P activated ChREBP.
Medium-chain acyl-CoA dehydrogenase deficiency
Residual activity of mitochondrial medium-chain fatty acid
oxidation in patients with MCAD deficiency in vivo
Heales et al measured the rate of oxidation of [1-13C]-
octanoate in patients with MCAD (EC# 1.3.8.7) deficiency
(MIM# 607008) (Heales et al 1994). They used a primed-
continuous intravenous infusion of [1-13C]-octanoate for 4 h
in four patients withMCAD deficiency after an overnight fast.
The rate of appearance calculated according to Eqs. (1) and (2)
ranged from 14.7 to 36.2 μmol.kg−1.min−1. Moreover, near
normal values were observed for the oxidation of octanoate in
t he s e pa t i e n t s , v a ry ing be tween 6 .4 and 13 .1
μmol.kg−1.min−1. On average 40.0% of the infused octanoate
was oxidized. The metabolic fate of the remaining 60% of the
infused labeled octanoate was not reported.
It has been hypothesized that ketogenesis is impaired in
patients with MCADD. Fletcher and Pitt (2001) measured
the rate of ketogenesis in three well children with MCADD
after 9 to 11 h fasting before starting the study period. They
used a primed-continuous infusion protocol of the sodium
salts of [1,3-13C2]-acetoacetate and [1,2,3,4-
13C4]-3-
hydroxybutyrate. They applied the two-accessible pool model
to estimate the rates of ketogenesis, interconversions, and ke-
tone utilization (Bougneres et al 1986).When compared to the
rates in six healthy children (Bougneres and Ferre 1987) no
differences were observed between healthy and affected chil-
dren. Apparently, in these well children, ketogenesis was not
impaired.
Animal models of mitochondrial fatty acid oxidation defects
Flux analysis of metabolism in various models of mitochon-
drial fatty acid oxidation (mFAO) defects has mainly been
focused on the consequences of these defects on glucose me-
tabolism. Patients with a defect of mFAO suffer from acute,
life-threatening episodes of hypoglycemia. The acute effects
of CPT-I inhibition by 2-tetradecylglycidic acid (TDGA) on
glucose metabolism have been studied in mice (Fig. 5) (Derks
et al 2008b). The authors applied the isotopic model of hepatic
glucose metabolism and the multiple tracer infusion and sam-
pling protocol as described above, with timed urine samples
collected at hourly intervals on filter paper and without the
inhibitor of the G6P transporter (Fig. 5a). Short term fasted
mice received a single injection of a bolus of TDGA 9 h before
the start of the experiment. At the start of the experiment, the
injected mice suffer from hypoglycemia in contrast to vehicle
treated mice. Changes in hepatic glucose metabolism were
subtle, with a small decrease in gluconeogenesis, glycogen
synthesis, and glucose phosphorylation. Irrespective of the
hypoglycemia glucose production remained unaffected. In
contrast, metabolic clearance rate of glucose increased consid-
erably from ~17 ml.kg−1.h−1 to ~28 ml.kg−1.h−1. The cause of
the inadequate rate of gluconeogenesis was not clear. Later
studies in mice with a knockout of long chain-acylCoA dehy-
drogenase (Houten et al. 2013) also observed no increase in
gluconeogenesis irrespective of low blood glucose concentra-
tions in fasted mice, applying the same methodology as in the
study with MCAD knockout mice. When in a separate exper-
iment an oral bolus of alanine was given, blood glucose con-
centration increased transiently, indicating a possible short
supply of gluconeogenic substrates. This observation has not
been followed up by a stable isotope experiment to estimate
gluconeogenesis in the presence of an alanine infusion. At this
moment it remains an open question whether delivery of
gluconeogenic substrates by peripheral tissue is hampered
resulting in an inadequate rate of gluconeogenesis.
The effects of MCAD deficiency on glucose metabolism
in vivo (Herrema et al 2008) were studied in mice with a
deletion of MCAD (Tolwani et al 2005) by the same methods
as described above. In vivo glucose metabolism was hardly
affected in the mice with MCAD knocked out (Fig. 6). Only
glycogen metabolism changed, while glucose production de-
creased slightly. Lipopolysaccharide (LPS) was used in an
effort to mimic in MCAD−/− mice the sudden deterioration
of the clinic of MCAD deficient patients. A single bolus of
LPS, to induce an acute phase response, resulted in a de-
creased blood glucose concentration from 6.2 ± 0.5 to 2.5 ±
0.5 mM in MCAD−/− mice, not different form WT mice (8.2
± 0.2 to 3.0 ± 0.5 mM). Glucose phosphorylation decreased
more strongly after administration of LPS in MCAD−/− mice
compared to WT mice. Moreover, the flux through gluconeo-
genesis decreased in MCAD−/− mice, even with the low glu-
cose concentrations in blood.
Until now, these studies have not been able to give us
detailed information on the mechanisms underlying the clini-
cal course of patients with a mFAO defect. Recently, the group
of Bakker and coworkers developed a kinetic model of the
mFAO (van Eunen et al 2013, van Eunen et al 2016,
Martines et al 2017). Simulations of the rate of oxidation of
palmitoyl-CoA at increasing concentrations of palmitoyl-CoA
showed that the ‘circular’ organization of the mFAO pathway
with promiscuous enzymes resulted in a sudden and rapid
decrease of the rate of the mFAO at high concentration of
palmitoyl-CoA. The flux through mFAO ‘collapsed’ because
the activity of medium-chain ketoacyl-CoA thiolase rapidly
deteriorated upon approaching the point of ‘collapse’
(Martines et al 2017). Concomitantly, free CoASH
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concentration decreases to very low values because of the
accumulation of acyl-CoA intermediates. When MCAD was
eliminated from the model, the initial rate of palmitate oxida-
tion did not differ from the rate calculated with MCAD pres-
ent. However, the point of ‘collapse’ was reached at far lower
concentrations of palmitoyl-CoA. One should be aware that
very low free CoASH concentrations in mitochondria also
severely interfere in pyruvate decarboxylation and TCA cycle
activity. This can result in an overall impairment of the mito-
chondrial function. This sequence of events might take place
in febrile MCADD patients upon fasting. Then metabolic de-
mands are high and concentrations of free fatty acids in the
circulation are high. In this respect it is of interest to note that
MCAD can play a role in the detoxification of xenobiotic
arylcarboxylates released by gut microbial metabolism.
Products of microbial metabolism in the gut, like
phenylpropionate and phenylbutyrate, are used as substrates
in the activity assay of MCAD (Rinaldo et al 1990, Derks et al
2008a, Kormanik et al 2012). Impaired metabolism of the
CoA thio-esters of arylcarboxylates might trap free CoASH
inmitochondria. The point of ‘collapse’ of fatty acid oxidation
will then be reached at low concentrations of long-chain acyl-
CoA. Hence, when MCAD is deficient the mFAO becomes
vulnerable for rapid sequestration of free CoASH already at
low concentrations of fatty acid with a sudden decrease in the
rate of fatty acid oxidation as a result.
Next to mitochondria, peroxisomes contribute significantly
to the oxidation of long-chain fatty acids (Wanders et al 2016,
Wanders 2014). The partitioning of the oxidation of fatty acids
of various chain-lengths over peroxisomes and mitochondria
was studied in isolated non-recirculating isolated rat heart and




































































Fig. 5 Effects of 2-tetradecylglycidic acid (TDGA) treatment on hepatic
carbohydrate metabolism in mice. Mice were injected with vehicle
(controls) or 30 mg/kg TDGA intraperitoneally and fasted for 9 h.
Subsequently, the 6-h infusion experiment was performed. White bars
show results in vehicle-treated mice, black bars in TDGA-treated mice.
Data are presented as mean ± SEM, n = 6. *P < 0.05. Source: (Derks et al
2008b), reproduced with permission from the American Association for
the Study of Liver Disease
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(Reszko et al 2004, Bian et al 2005, Kasumov et al 2005).









C12:0-n-dicarboxylic acid. They used the
13C–labeling ratio
of malonyl-CoA enrichment over the enrichment of the ace-
tate moiety of citrate to estimate the partitioning of fatty acids
over peroxisomal FAO (pFAO) and mFAO. The observed
13C–labeling ratios indicated that, as expected, long-chain fat-
ty acids were oxidized in mitochondria. However, concomi-
tantly, they were vividly oxidized in peroxisomes till C6:0-n-
carboxylic acid, followed by oxidation in mitochondria. This
became clear when the 13C–labeling ratios were compared
when [1-13C]-C8:0-n-carboxylic acid was infused with the ra-
tio when [3-13C]-C8:0-n-carboxylic acid was infused. Only
[1-13C]-C8:0-n-carboxylic acid resulted in a
13C–labeling ratio
indicative of both pFAO and mFAO. Oxidation of [3-13C]-
C8:0-n-carboxylic acid resulted in
13C labeling ratios indica-
tive of mFAO. Transfer of 13C from [1,12-13C2]-C12:0-n-dicar-
boxylic acid was only to malonyl-CoAwithout labeling of the
acetate moiety of citrate, indicating that oxidation started ex-
clusively in peroxisomes. These results show that pFAO of
long-chain acyl-CoA till hexanoyl-CoA contributes to the to-
tal oxidative capacity in rat liver and heart. It is not clear from
the results how important pFAO is in quantative terms, since
the authors did not estimate the total rate of fatty acid oxida-
tion or the turnover of malonyl-CoA. The authors conclude
that pFAO supplies acetyl-CoA for malonyl-CoA synthesis
and subsequently for lipogenesis. Indeed, Oosterveer et al
(2009) observed label incorporation of [2-13C]-acetate into
palmitate indicating lipogenesis in VLDL inmice during treat-
ment with fibrates, which stimulated mFAO and pFAO.
Wanders et al (2010) proposed fatty acid ω-oxidation
(ωFAO) by the CYP4A/F subfamilies and subsequent perox-
isomal oxidation of the resulting dicarboxylic acids as a rescue
pathway in mFAO disorders. Jin and coworkers (Jin et al
2015) studied the partitioning of [U-13C]-C12-, [U-
13C]-C9-,
and [U-13C]-C5-n-dicarboxylic acids over mFAO and pFAO
in perfused isolated rat livers by measuring the labeling of
various acetyl-CoA proxies. [U-13C]-C12:0-n- and [U-
13C]-
C9:0-n-dicarboxylic acids were partially oxidized in peroxi-
somes with terminal oxidation in mitochondria. This is in line
with the observation of label transfer of 13C from [1,12-13C2]-
C12:0-n-dicarboxylic acid to malonyl-CoA catalyzed exclu-
sively by peroxisomes. Furthermore, they observed that
oxidation of [U-13C]-C5:0-n-dicarboxylic acid (glutaric ac-
id) occurred in mitochondria without a contribution of
peroxisomes. As has been noticed above, the authors did
not estimate absolute oxidative rates of ωFAO of long-
chain fatty acids followed by pFAO of dicarboxylic acids.
So, it remains unclear how important these contributions
are to the total flux of FAO.
In conclusion, in mice with an mFAO defect, the supply of
gluconeogenic substrates appeared to be limited, while the ca-
pacity of gluconeogenesis seems not to be affected. Peripheral
proteolysis might be too low to supply substrates in adequate
amounts. The question arises whether there is a place for a
protein-enriched diet in the treatment of mFAO deficiencies.
The role of pFAO and ωFAO in patients with a defect in
mFAO clearly warrants further study (see Violante et al 2013,
Wanders et al 2016). The question arises of how important
pFAO is in humans in comparison with mFAO. In this respect,
the clinical trials with PPARα-ligand benzofibrate are of inter-


















































































Fig. 6 Effects of
lipopolysaccharide (LPS) treat-
ment in MCAD-deficient mice.
Wild-type and MCAD−/− mice
were injected with saline (-LPS)
or LPS (+LPS) followed by a 9-h
fast. The 6-h infusion experiment
was performed subsequently.
Graphs on each arrow represent
the flux of the pathways as ex-
plained in Fig. 3.White bars show
results in wild-type mice, black
bars in MCAD–/– mice. Data are
presented as the mean ± SEM,
n = 6. #P < 0.05 between groups.
*P < 0.05 within groups. Source:
(Herrema et al 2008), reproduced
with permission from the
American Association for the
Study of Liver Disease
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Propionic and methylmalonic aciduria
Propionate metabolism in patients with propionic
and methylmalonic aciduria
The remaining capacity to detoxify propionic acid in patients
with PA (MIM# 606054) or MMA (MIM# 2510000)
had been measured by Thompson and coworkers
(Thompson et al 1990b) (Thompson et al 1990a). In these
patients detoxification of propionate is severely hampered
due to the deficiency of propionyl-CoA carboxylase (EC#
6.4.1.3) or methylmalonyl-CoA mutase (EC# 5.4.99.2).
Propionic acid is the product of the oxidation of the amino
acids valine, isoleucine, methionine, and threonine; but more
importantly, propionic acid is one of the short-chain fatty acids
(SCFAs) produced in high amounts by the gut microbiota
together with acetate and butyrate (Besten et al 2014).
Thompson and coworkers infused three children with PA
and three children with MMAwith a multi-tracer solution of
[1-13C]-propionate, [ring-5H2]-phenylalanine and [1-
13C]-ty-
rosine. The infusion of [ring-5H2]-phenylalanine and [1-
13C]-
tyrosine was used to calculate the rate of phenylalanine hy-
droxylation as a measure of protein catabolism and the rate of
irreversible catabolism of the amino acids valine, isoleucine,
methionine, and threonine. The appearance rate of propionate
into the systemic circulation in the three children with PAwas
0.75, 0.76, and 0.82μmol.kg−1.min−1 and in the three children
with MMA 1.92, 1.45, and 0.77 μmol.kg−1.min−1. When pa-
tients were treated with the antibiotic metronidazole to elimi-
nate propionate production by the gut microbiota, propionate
production decreased 22 ± 8%. Very recently Boets et al mea-
sured the rate of appearance in the systemic circulation of
SCFA in healthy adults (Boets et al). The estimated appear-
ance rate of propionate was 0.27 ± 0.09 μmol.kg−1.min−1 (n =
12) considerably less than in patients with PA and MMA.
Next, Thompson and coworkers estimated the oxidation of
propionate in the same patients (Thompson et al 1990b). In
t h e c h i l d r e n w i t h PA , o x i d a t i o n w a s 0 . 1 8 –
0.60 μmol.kg−1.min−1, and in the children with MMA,
0.25–1.08 μmol.kg−1.min−1. Lower oxidation rates were ob-
served in healthy subjects (0.08–0.32 μmol.kg−1.min−1).
These values were, however, not corrected for differences in
circulating propionate concentrations.
Propionate metabolism in ex vivo models
Apparently, an alternative pathway for oxidation of propionate
might be operative in patients with PA or MMA. In the 1970s
Ando et al (Ando et al. 1972a, Ando et al. 1972b) alluded to
the possibility of a modified β-oxidation pathway of propio-
nate. Recent studies in C. elegans and HepG2 cells (Watson
et al 2016) showed the existence of such an alternative oxida-
tion pathway (Fig. 7). In humans this pathway consists of five
enzymes starting at propionyl-CoA dehydrogenation by
ACADSB (EC# 1.3.8.5), hydration of the product acrylyl-
CoA by ECHS1 (EC# 4.2.1), after which the product 3-
hydroxypropionyl-CoA is hydrolyzed by HIBCH (EC#
3.1.2.4) and 3-hydroxypropionate is formed. Further oxida-
tion to malonic semialdehyde is catalyzed by the
transhydrogenase ADHFE1 (a.k.a. HOT) (EC# 1.1.99.24),
while reducing 2-ketoglutarate into D-2-hydroxyglutarate.
Finally, malonic semialdehyde is oxidative decarboxylated
by ALDH6A1 (EC# 1.2.1.27) into acetyl-CoA and CO2.
Experiments with [U-13C]-propionate in the presence and
absence of labeled and unlabeled 3-hydropropionate by
Wilson and coworkers (Wilson et al 2017) in non-
recirculating perfused isolated rat liver were fully compatible
with the presence of the proposed modified β-oxidation for
propionate. Labeling of 3-hydroxypopionate by [U-13C]-pro-
pionate was almost complete. Appreciable amounts of M2
acetyl-CoA were observed indicative of the presence of the
modified β-oxidation pathway. As expected, extensive label-
ing of succinate was also observed via the canonical, vitamin
B12 dependent pathway, with M3 succinate originating from
the incorporation of infused M3 [U-
13C]-propionate and M2
succinate due to recycling of M3 succinate through the TCA
cycle. The addition of 3-hydroxypropiopnate to the perfusate
altered the MID of succinate profoundly. The fractional con-
tribution of M2 succinate almost disappeared, pointing to a
strong inhibition of the TCA cycle by 3-hydroxypropionate.
In conclusion, the observations made by Thompson and
coworkers deserve to be re-investigated in light of these new
findings. When one considers stimulation of the modified β
oxidation pathway as a therapeutic option in patients with
propionic and methylmalonic aciduria, one should realize that
intermediates in this pathway are cytotoxic, in contrast to the
canonical vitamin B12-dependent pathway via methylmalonate
and succinate. Appreciable reaction rates will only be obtain-
ed at elevated concentrations of propionate such as observed
in patients with propionic and methylmalonic aciduria.
Urea cycle defects
Estimation of the urea synthetic flux in vivo in patients
with urea cycle defects
Hepatic urea synthesis is the major pathway by which virtu-
ally all terrestrial mammals rid themselves of excess nitrogen.
Major sources of nitrogen are portal ammonia derived from
host urea hydrolyzed by bacterial urease in the gut, the activity
of portal glutaminase, and whole-body amino acid oxidation
(Veeneman et al 2004). UCDs come in a wide spectrum of
clinical presentations. Hence, it becomes of importance to
have a method that estimates the residual activity of the urea
cycle when one of the enzymes is deficient. In vivo urea syn-
thesis in healthy subjects and patients with a UCD has been
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estimated during a primed-continuous intravenous infusion of
[18O]-urea or [13C]-urea and measurement of isotope dilution
of labeled urea in blood. The values obtained for urea synthe-
s i s i n h e a l t h y sub j e c t s v a r i e d b e tween 3 . 7 ±
0.2 μmol.kg−1.min−1 (Matthews and Downey 1984), 2.2 ±
0.3 μmol.kg−1.min−1 (Lee et al 2000), and 3.6 ±
0.5 μmol.kg−1.min−1 (Scaglia et al 2003). Our measurements
in adult nephrotic patients by a different, kinetic isotopic
method gave a value of 3.4 ± 0.2 μmol.kg−1.min−1
(Veeneman et al 2004). Subsequently, urea synthesis in treated
patients had been estimated (Lee et al 2000). In patients with a
null mutation of one of the genes encoding for the enzymes of
the urea cycle the rate of urea synthesis was not different from
0 μmol.kg−1.h−1 (−0.01 ± 0.03 μmol.kg−1.min−1), after cor-
rection for urea production of therapeutic arginine and citrul-
line supplementation. To circumvent this correction the au-
thors used an infusion protocol with [5-15 N]-glutamine and
measured the molar enrichment of [5-15 N]-glutamine and
[15N]-urea to estimate the transfer of 15N from glutamine to
urea. They expressed the extent of transfer as a ratio of [15N]-
urea enrichment over [5-15 N]-glutamine enrichment (Scaglia
et al 2002, Lee et al 2000). They observed a ratio of 0.42 ±
0.06 in healthy controls, 0.003 ± 0.007 in patients with a null
mutation, and intermediate values in the other groups of urea
cycle defects (0.16 ± 0.04 to 0.35 ± 0.11). No relation was
observed between the severity of the disease in each of the
patients individually and their value of the ratio, only groups
of patients could be distinguished.
Scaglia and coworkers (Scaglia et al 2003) studied the first
pass extraction of orally given 15NH4Cl in healthy subjects
and in female OTC carriers. In healthy subjects 61 ± 8% of
the enteral supplied 15N was transferred to urea by the liver on
the first pass. A total of 17 ± 8% of the orally supplied 15Nwas
recovered in glutamine and 22 ± 6% escaped extraction on the
first pass by the liver. In female OTC carriers first pass transfer
of nitrogen by the liver from orally supplied 15NH4Cl to urea
decreased to 11 ± 8% and the transfer to glutamine increased
to 29 ± 8%. A total of 60 ± 6% of enteral 15NH4Cl escaped the
first pass. No difference was observed in the final extent of la-
bel incorporation of orally administered tracer into urea be-
tween the two groups (81 ± 4% vs 72 ± 4%, mean ± SE,
healthy subject vs OCTD carriers, respectively). Next, they
studied the effect of phenylbutyrate on nitrogen metabolism
in healthy subjects and partial-OTC deficient female subjects.
Phenylbutyrate is a drug used in patients suffering from a
UCD to induce alternative pathways of nitrogen disposal.
Al l subjec t s rece ived a phenylbutyra te dose of
~5.6 g.kg−1.d−1. In control subjects urea synthesis decreased
from amean of 3.0 to 2.6 μmol.kg−1.min−1 and in partial-OTC
deficient female subjects from 2.6 to 2.0 μmol.kg−1.min−1.
Phenylbutyrate did not affect protein catabolism, the whole-
body turnover of glutamine, leucine, phenylalanine, and tyro-
sine nor the hydroxylation of phenylalanine into tyrosine. The
clearance of leucine increased by 61% which resulted in a
decreased leucine concentration in the bloodstream.
Tracer-based studies of nitrogen metabolism in model
systems
In the liver an enteral nitrogen load is partitioned over irrevers-
ible disposal by the urea cycle and preservation by incorpora-
tion of nitrogen into glutamine. Until now most tracer studies
with stable isotopes have been performed in non-recirculating
perfused isolated liver preparations without a UCD (Brosnan
et al 1996, Brosnan et al 2004, Nissim et al 1996, Nissim et al
1992, Nissim et al 2003, Nissim et al 1999). In urea two N-
atoms are present, one derived from NH3 and one from aspar-
tate. Accordingly, MIDAwas applied to analyze the 15N–label-
ing pattern of urea with [ureido-15 N]-citrulline and [2-15 N]-
aspartate in the effluent as proxies of the immediate precursor
Fig. 7 Schematic representation of the two metabolic pathways of
propionate in humans. a The canonical vitamin B12 dependent pathway
of propionate conversion into succinate. b The modified β-oxidation
pathway of propionate with cytotoxic intermediates. MM-
methylmalonyl , 3HP-3-hydroxypropionate, MSA-malonic
semialdehyde. Source: (Watson et al 2016). Reproduced with permission
from the publisher of eLife journal
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enrichment of mitochondrial carbamoylphosphate and cytosol-
ic aspartate, respectively. The transfer of 15N to urea was stud-
ied from 15NH3, [2-
15 N]-alanine, and glutamine labeled at the
amino-N ([2-15 N]-glutamine), the amide-N ([5-15 N]-gluta-
mine) or fully labeled ([2,5-15 N2]-glutamine). Collectively,
the studies pointed to the important role of mitochondrial glu-
tamate formation via reductive amination of 2-ketoglutarate by
glutamate dehydrogenase in the detoxification of ammonia by
supplying aspartate-N for transamination of oxaloacetate into
aspartate by glutamate. The amide-15 N in [5-15 N]-glutamine
was preferentially transferred to carbamoylphosphate.
Furthermore, [2-15 N]-alanine and 15NH3 provided both
nitrogen-atoms of urea but the transfer of 15N via aspartate
was preferred by [2-15 N]-alanine while the transfer via citrul-
line was preferred by 15NH3. Perfusion of livers with NH4Cl
strongly increased the negative nitrogen balance of perfused
isolated rat liver indicative of increased hepatic proteolysis to
supply enough aspartate-N to the urea cycle. Similar conclu-
sions were reached by Yang et al (2000) in fasted dogs.
Apparently, supply of glutamate by reductive amination of 2-
ketoglutarate was inadequate to deal with the high demand of
aspartate-N when supply of ammonia was high. Glutamate
synthesis in liver mitochondria appeared to be central to am-
monia detoxification.
Recent studies by Lamers and coworkers have put the results
of these studies in isolated rat liver into awhole body perspective
(He et al 2010, Hakvoort et al 2017). They studied intestinal
ammonia detoxification in control mice and in mice with a liver
knockout of glutamine synthetase. They showed that in mice
~30% of the infused ammonia is not cleared by the liver on first
pass, independent of portal ammonia concentrations ≤2mMand
an in t e s t i na l in fus ion o f ammonia ≤166 μmol
NH4CO3.kg
−1.min−1. Detoxification of the part of intestinal in-
fused ammonia absorbed by the liver (~70%) was equally
partitioned over urea synthesis (~35%) and glutamine synthesis
(~35%). During an intravenous infusion of NH4CO3, detoxifi-
cation of systemic ammonia was almost entirely dependent on
glutamine synthesis in muscle at an infusion rate ≤ 20 μmol
NH4CO3.kg
−1.min−1. Next, the transfer of the amide-N of glu-
tamine to urea was studied in control mice and mice with liver
and muscle knockout of glutamine synthetase using a multi
tracer primed-continuous infusion protocol with [5-15 N]-gluta-
mine and [18O,15N2]-urea and the measurement of the dilution
of [5-15 N]-glutamine and [18O,15N2]-urea and the appearance of
[15N]-urea in the circulation. The whole-body rate of appearance
of newly synthesized glutamine, traced with [5-15 N]-glutamine,
was closely correlated with the rate of transfer of amide-N of
newly synthesized glutamine to urea (measured as [15N]-urea),
without changes in total urea production, measured with
[18O,15N2]-urea. These studies clearly point to the pivotal role
of glutamine in whole body nitrogen metabolism.
Marini and coworkers (Matini et al 2005, Marini et al
2006a, Marini et al 2006b) studied urea synthesis in wild-
type mice and in mice hypomophic for ornithine
transcarbamoyltransferase (EC# 2.1.3.3) (OTCspf-ash). In nor-
mal mice theymeasured urea synthesis by isotope dilution of a
single intravenous bolus injection of [15N2]-urea and by
primed continuous intravenous infusion of the same label.
The rate of urea synthesis was 56 ± 12 μmol.kg−1.min−1 an
order of magnitude greater than reported in humans. Urea
synthesis in OTCspf-ash mice was not different from control
mice (52 ± 11 μmol.kg−1.min−1). When control mice and
OTCspf-ash mice were fed a complete mixture of amino acids
at ~200 μat N.kg−1.min−1, no difference was observed in the
ability to synthesize urea (mean: 107 vs 108 μmol.kg−1.min−1,
control vs OTCspf-ash mice, respectively). In contrast, when
OTCspf-ash mice were fed an unbalanced mixture of glycine
and alanine at a molar ratio of 1:2 without other amino acids,
at ~200 μat N.kg−1.min−1 no increase was observed in urea
synthesis (mean: 71 vs 53 μmol.kg−1.min−1, control vs
OTCspf-ash mice). When OTCspf-ash mice fed the glycine-
alanine mixture were intravenously infused with ornithine at
53 μmol.kg−1.min−1 urea synthesis normalized (mean: 75 vs
76 μmol.kg−1.min−1, control vs OTCspf-ash mice). Apparently,
the complete mixture of amino acids generated enough orni-
thine to allow OTCspf-ash mice to cope with the increased
nitrogen load of the complete mixture of amino acid. We can
compare this outcome with results of experiments where the
effect was studied of perfusion of isolated rat liver with a
solution of NH4Cl (see above). Liver weight decreased and
the conclusion was drawn that protein catabolism was en-
hanced to supply adequate amounts of aspartate-N to detoxify
ammonia. The experiments in OTCspf-ash mice point to the
importance of the supply of ornithine or of its precursor argi-
nine when the urea cycle is ‘broken’. For some UCDs this is
part of the clinical management of patients.
In conclusion, not all ammonia supplied by the gut is con-
verted into urea upon first pass by the liver. The remainder is
transferred to glutamine or enters the systemic circulation where
glutamine synthesis in peripheral tissue transfers ammonia-N to
glutamine. The supply of 2-ketoglutarate in liver mitochondria
plays an important role to supply glutamate. Newly synthesized
glutamine from glutamate is a major precursor of urea synthesis.
The study of whole-body nitrogen metabolism in models of
UCDs holds the key to new modalities of treatment of these
patients as is already shown by the studies in OTCspf-ash mice.
One might hypothesize that supplying precursors of glutamine
synthesis alleviates the hyperammonemia (Hakvoort et al 2017).
Moreover, oral supplementation with ornithine might also alle-
viate or even prevent hyperammonemic periods, particularly for
female OTC carriers.
Phenylketonuria
In three studies the residual activity of phenylalanine hydrox-
ylation was measured in PKU patients (MIM# 261600)
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(Thompson et al 1990b; Thompson and Halliday 1990; van
Spronsen et al 1998). In PKU patients the enzyme that con-
verts phenylalanine into tyrosine (phenylalanine 4-
monooxygenase (EC 1.14.16.1)) is deficient. A multi tracer
primed-continuous infusion of a solution of [phenyl-2H5]-phe-
nylalanine and [1-13C]-tyrosine was given to PKU patients
and during infusion blood samples were drawn. Isotope dilu-
tion was measured of [phenyl-2H5]-phenylalanine, [1-
13C]-ty-
rosine, and [phenyl-2H4]-tyrosine, the hydroxylation product
of [phenyl-2H5]-phenylalanine. Thompson and coworkers
(Thompson and Halliday 1990, Thompson et al 1990b) ob-
served an almost normal rate of hydroxylation of phenylala-
nine in PKU patients of 0.08 ± 0.04 μmol.kg−1.min−1, com-
pared to healthy subjects 0.10 ± 0.03 μmol.kg−1.min−1. In two
patients with hyperphenylalaninemia, hydroxylation of phe-
nylalanine was 0.07 and 0.09 μmol.kg−1.min−1. No relation-
ship was observed between the apparent rate of hydroxylation
and the concentration of phenyalanine in blood during the
study. Applying the same experimental protocol Van
Spronsen et al came to a completely different conclusion
(van Spronsen et al 1998). In PKU patients they estimated
the rate of phenylalanine hydroxylation to be 0.006 ±
0.002 μmol.kg−1.min−1. Their values in two healthy subjects
were 0.10 and 0.07 μmol.kg−1.min−1, fully compatible with
the values observed by Thompson and coworkers. No relation
was found between the hydroxylation rate and the tolerance to
natural protein in the diet. The reason for the lack of correla-
tion of phenylalanine hydroxylation and measures of clinical
severity is not clear. It might be that other as yet unknown
pathways exist which metabolize phenylalanine. Bacterial
metabolism might have interfered with the measurements of
phenylalanine metabolism. To a certain extent, this might be
similar to the case of host urea, which is hydrolyzed in the
intestine by bacterial urease. When [2H5]-phenylalanine is hy-
drolyzed by bacterial phenylalanine ammonia lyase (EC
4.3.1.24) it escapes conversion into tyrosine (Clayton 2012).
In this way phenylalanine leaves the circulation by two routes,
and only one is traced by the experimental set up.
Tracer-based studies of citrate metabolism
in fibroblasts of patients with combined
D,L-2-hydroxyglutaric aciduria
The group of Struys studied metabolic reprogramming in fi-
broblasts of patients lacking the citrate transporter (unpub-
lished observations). Deficiency of the mitochondrial citrate
transporter (SLC25A1) results in combined D- and L-2-
hydroxyglutaric aciduria (MIM#615182) (Nota et al 2013).
Citrate is central to TCA cycle and it caries acetyl-units gen-
erated by pyruvate dehydrogenase or fatty acid oxidation from
the mitochondrial matrix into the cytosol to supply acetyl-
CoA to de novo lipogenesis, cholesterol synthesis (Fig. 8a,
b) and histone acetylation (Wellen et al 2009). Control and
patient fibroblasts were incubated with M5 [U-
13C]-gluta-
mine. Conversion of the carbon skeleton of glutamine into
citrate proceeds partly in the mitochondrion and partly in the
cytosol via successive deamidation and deamination of gluta-
mine to 2-oxoglutarate in mitochondria and reductive carbox-
ylation of 2-oxoglutarate to isocitrate catalyzed by cytosolic
isocitrate dehydrogenase 1 (Mullen et al 2011) (Metallo et al
2011). In control fibroblasts, a prominent fractional contribu-
tion of M4 citrate to the MID of citrate was observed.
Mitochondrial M5 2-oxoglutarate fromM5 [U-
13C]-glutamine
is converted into M4-oxaloacetate by the TCA cycle.
Furthermore, cytosolic M5 citrate fromM5 [U-
13C]-glutamine
enters the mitochondria and is also converted into M4 oxalo-
acetate (Fig. 8b). Very little M5 citrate was observed in control
fibroblasts. In patient fibroblasts, however, a high fractional
contribution of M5 citrate to the MID of citrate was observed,
confirming the severely impaired entrance of cytosolic citrate
into mitochondria in patient fibroblast for further oxidation.
Next, the fate of the label was followed into cholesterol, a
kind of ‘13/14-polymer’ of acetate (Hellerstein and Neese
1992; Kelleher et al 1994). Acetate used in the cholesterol
synthesis comes partially from citrate. Labeling of citrate by
acetate coming from [U-13C]-glucose takes place inside mito-
chondria and labeled citrate needs to be exported to provide
acetate for the cholesterol biosynthesis (Fig. 8a). When con-
trol fibroblasts were incubated with [U-13C]-glucose the frac-
tional contribution of M6–M10 mass isotopomers dominated
the MID of cholesterol, indicative of considerable labeling of
acetate pool. In patient fibroblasts a shift was observed to
lower mass isotopomers of cholesterol indicative of less effi-
cient labeling of acetate. The transport of mitochondrial la-
beled citrate to the cytosol was severely impaired when
SLC25A1 is deficient.
Synthesis of citrate from glutamine takes place in the
cytosol by reductive carboxylation of 2-ketoglutarate (Fig.
8b). M5 [U-
13C]-glutamine gives rise to M5 citrate in the
cytosol, which is split into M3 oxaloacetate and M2
acetyl-CoA by ATP-citrate lyase. When control fibro-
blasts were incubated with [U-13C]-glutamine a minor
con t r i bu t ion of M2 cho le s t e ro l was obse rved .
Apparently, in control fibroblasts glutamine-derived ace-
tyl-CoA is of very limited importance in the supply of
acetate to cholesterol biosynthesis. In patient fibroblast,
however, the picture was quite different with an increased
fraction of M4 cholesterol, indicative for a more promi-
nent labeling of acetyl-CoA by [U-13C]-glutamine. In the
absence of the mitochondrial citrate transporter glutamine
became a donor of acetate-units to cholesterol synthesis.
The results of this study are very similar to those obtained
in the lung tumor cell line H460 (Jiang et al 2016). SLC25A1
has been implicated in tumor progression (Kolukula et al
2014, Catalina-Rodriguez et al 2012). Among other things,
Jiang et al studied the transfer of 13C from [U-13C]-glucose
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and [U-13C]-glutamine to palmitate, the ‘octamer’ of the
monomer acetate. After incubation of H460 cells with
[U-13C]-glucose palmitate MID was dominated by M10–M16
mass isotopomers, indicative of a high flux of M2 citrate from
the mitochondria into the cytosol resulting in a very efficient
labeling of the cytosolic acetate pool. Deletion of SLC25A1
by CRISPR/Cas9 shifted the fractional contribution of the
dominant mass isotopomers of the MID of palmitate to lower
mass isotopomers (M2–M8), reflecting a restricted efflux of
M2 citrate from mitochondria into the cytosol with a lower
efficiency of labeling of the acetate pool for palmitate biosyn-
thesis. When H460 cells were incubated with [U-13C]-gluta-
mine, only M2–M4 mass isotopomers were observed in the
MID of palmitate. After deletion of SLC25A1 labeling effi-
ciency of acetate by [U-13C]-glutamine increased, with M6–
M10 as the dominant mass isotopomers of palmitate.
Conclusions and future perspectives
In Table 1 an overview is given of the major results and pos-
sible therapeutic consequences of the studies on metabolic
reprogramming in patients with an IEM and related model
systems with stable isotopes. The summary clearly shows that
whole body metabolism adapts in a way which was quite
unexpected and which was very specific for each of the
IEMs individually. It clearly points to the need of in vivo
studies both in patients and in animal models of IEM.
Besides studying reprogrammed metabolism, it also be-
came clear that the study of the role of gut microbiota in the
clinical presentation of IEMs urgently needs closer examina-
tion. In mFAO the rate of microbial synthesis of products like
arylcarboxylates, in PA and MMA of SCFA, and in UCDs of
ammonia might be of importance to understand the broad
spectrum of clinical presentation of IEMs. There are ample
studies showing that both human genetic variation and diet
have clear effects on the composition of the gut microbiota,
predisposing to microbiome dysbiosis (see (Hall et al 2017)
for a review). It can be expected that also in the case of IEM,
microbiome composition is altered and possibly leads to
microbiome dysbiosis.
In only a limited set of IEM extensive studies have been
performed. More model systems are required to address the
many issues in the pathology of IEMs. Genetically modified
mice are themainmodel system, but they have their drawbacks.
A clear example is the GALT knockout mice model for galac-
tosemia, which did not show the clinical phenotype seen in
children suffering from galactosemia (Leslie et al 1996). The
use of zebrafish as an alternative to mice is an emergent field
(Wager et al 2014). New cell models and methods offer new
opportunities for the study of IEM (Wangler et al 2017).
Great progress has been made in the development of in-
duced specific cell types starting from patient fibroblasts (Xu
et al 2015). New methods in tracer-based metabolomics al-
lows for fingerprinting of metabolism with unsupervised non-
targeted tracer fate detection (Hiller et al 2013; Weindl et al
2016). Mathematical models are continuously being improved
to convert the observed MIDs of metabolites into flux pattern
(for reviews see (Buescher et al 2015; Vasilakou et al 2016)).
In tumors, metabolism is also forced to reprogram itself
because of mutations in genes coding for proteins involved
in cellular growth and associated metabolism. Sometimes, en-
zyme deficiencies known in the field of IEMs results in tumor
formation, showing the overlap of both fields with respect to
the many ways metabolism can reorganize itself (see (Erez
and DeBerardinis 2015; DeBerardinis and Thompson 2012)
for reviews). Many metabolic studies in tumors testify to the
extreme versatility of metabolism to sustain maintenance and
growth of cells (see (Wong et al 2017) for a review).
Systems biology might offer a new way to integrate multi-
omics data into molecular networks (Argmann et al 2016).
Fig. 8 Schematic representation of TCA cycle and cytosolic metabolism
of TCA intermediates. a Schematic representation of mitochondrial (m)
and cytosolic (c) citrate metabolism and carbon atom transitions for
[U-13C]-glucose (b) idem for [U-13C]-glutamine. Black circles represents
aliphatic atoms, red circle represents carboxylic carbon atoms. Open
circles represent unlabeled carbon atoms. Closed circles represent 13C
labeled carbon atoms. Glc – glucose, Pyr – pyruvate, Ac – acetylCoA,
Cit – citrate, Isocit – isocitrate, αOG – 2-ketoglutarate, Suc – succinate,
Fum – fumarate, Mal – malate, Oxac – oxaloacetate, E-glutamate, Q-
glutamine
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Recently, a community-driven global reconstruction of human
metabolism resulted in the comprehensive genome-scale met-
abolic map Recon 2 (Thiele et al 2013). This metabolic map
has already been used to predict additional metabolic bio-
markers of IEMs (Sahoo et al 2012; Thiele et al 2013;
Shlomi et al 2009). One might use this map not only to predict
biomarkers but also to diagnose as yet unknown inborn errors
of metabolism by projecting abnormal metabolite profiles and
genome-wide exome sequence data onto thismap. This is now
actively pursued in the Undiagnosed Diseases Network in the
USA and internationally (Taruscio et al 2015; Ramoni et al
2017; Austin et al 2017). The map can also be used to eluci-
date affected pathways in known inborn errors of metabolism.
In this way the targeted approach applied for instance in the
study of lysine metabolism (Struys and Jakobs 2010; Posset
et al 2014) to elucidate defective metabolic pathways, can
now be transformed into a genomic-wide approach. Very
recently, a systems biology approach has been undertaken to
integrate Recon-2 with metabolomics data of the NCI-60 pan-
el of 60 well characterized primary human cancer cell lines
established from nine common tumor types (Jain et al 2012,
Aurich et al 2017). The results of extracellular metabolomics
reflecting uptake and release of metabolites were used to gen-
erate condition- and cell-specific metabolic models of the can-
cer cell lines. Next, these metabolic models were analyzed for
their capability to harvest energy and generate cofactors. This
analysis revealed the different strategies cells can use to cope
with environmental and genetic perturbations. Stable isotope
based metabolomics can then be used to test the hypotheses
generated. This looks a very promising way to study metabol-
ic reprogramming of patient fibroblasts or fibroblast-derived
induced specific cell types.
Textbook knowledge is clearly insufficient to deduce the
way metabolism copes with an enzyme deficiency.
Table 1 Summary of results of
flux analysis in IEM IEM Results
GSD Ia - Appreciable postprandial glucose production
- Glucose production is due to glucosidase activity in liver
- Intracellular de novo lipid metabolism is strongly enhanced
- Lipoprotein metabolism seems to be impaired with reduced lipolysis
- Metabolic reprogramming is driven by the transcription factor ChREBP activated by G6P
MCADD - Normal oxidation of medium-chain fatty acids.
- The hypoglycemia is driven by a persistent increased consumption of glucose by peripheral
tissue and an inadequate production of glucose by gluconeogenesis
- Supply of gluconeogenic substrates by peripheral tissue might be too low.
- A protein-enriched diet might be an additional therapeutic option for patient with MCADD
to boost gluconeogenesis to prevent a hypoglycemic hypoketotic crisis.
- There might be an additional role of peroxisomes and endoplasmic reticulum to fatty acid
oxidation
PMA - Propionate oxidation is almost higher in patients with PMA than in healthy volunteers
- Gut microbiota are an important producer of propionate
- A modified β oxidation pathway of propionate exists in humans, with cytotoxic
intermediates
- Changing the microbiota composition by dietary intervention might be a therapeutic option
UCD - First pass absorption by the liver of ammonia from the gut is ~70% and 30% enters
the systemic circulation.
- Direct conversion of ammonia into urea upon first pass is limited to 35% of the supplied
ammonia.
- Remainder of supplied ammonia is used in the synthesis of glutamine, in liver and inmuscle
- Glutamine is central in whole body nitrogen metabolism and in urea synthesis
- 2-Ketoglutarate supply in hepatic mitochondria is an important precursor in whole body
glutamate and glutamine synthesis
- Additional gifts of glutamate to enhance glutamine synthesis during hyperammonemic
events might be an additional therapeutic option
- Re-interpretation of changes in glutamine concentration in blood during the monitoring of
therapy might be necessary
PKU - There is an as yet unidentified pathway of phenylalanine oxidation.
D,L-2OHG-uria - Preliminary results in fibroblast point to a shift from glucose to glutamine to support lipid
and cholesterol synthesis
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Metabolism and its regulation appear to be too versatile.
Methods are now available to generate hypotheses about the
flux distribution in the case of IEMs on a genome-wide scale
and cell specific. Stable isotopes methodology is the tool to
test these hypotheses. Hopefully, these new technologies will
help us to get a better understanding of how metabolism is
reprogrammed in patients with an IEM such that we are able to
offer these patients better treatments for a better life.
Acknowledgements The author thanks the anonymous referees for this
journal for their excellent comments which significantly improved this
paper. The author apologizes to colleagues whose work could not be cited
due to space limitations. The author greatly appreciated the generosity of
Dr. EA Struys (VU University, Amsterdam, The Netherlands) for com-
municating the results obtained in SLC25A1 deficient fibroblast before
publication. The author thanks Drs. BM Bakker, TH van Dijk, K van
Eunen, AK Groen, F Kuipers, and MH Oosterveer for many stimulating
discussions. The author gratefully acknowledges the fruitful collaboration
with the pediatricians Drs. Derks, Smit, and Van Spronsen. The work in
the author’ laboratory was financially supported by the Dutch Kidney
Foundation, Health Insurers Innovative Foundation, Top institute Food
and Nutrition, Netherlands Consortium for Systems Biology, ZonMW
and NWO.
Compliance with ethical standards
Conflict of interest None.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Ando T, Nyhan WL, Connor JD et al (1972a) The oxidation of glycine
and propionic acid in propionic acidemia with ketotic
hyperglycinemia. Pediatr Res 6:576–583. https://doi.org/10.1203/
00006450-197206000-00006
Ando T, Rasmussen K, Nyhan WL, Hul l D (1972b) 3-
hydroxypropionate: significance of -oxidation of propionate in pa-
tients with propionic acidemia and methylmalonic acidemia. Proc
Natl Acad Sci U S A 69:2807–2811
Argmann CA, Houten SM, Zhu J, Schadt EE (2016) A next generation
multiscale view of inborn errors of metabolism. Cell Metab 23:13–
26. https://doi.org/10.1016/j.cmet.2015.11.012
Aurich MK, Fleming RMT, Thiele I (2017) A systems approach reveals
distinct metabolic strategies among the NCI-60 cancer cell lines.
PLoS Comput Biol 13:e1005698. https://doi.org/10.1371/journal.
pcbi.1005698.s002
Austin CP, Cutillo CM, Lau LPL et al (2017) Future of rare diseases
research 2017-2027: an IRDiRC perspective. Clin Transl Sci.
https://doi.org/10.1111/cts.12500
Bandsma RH,Wiegman CH, Herling AWet al (2001) Acute inhibition of
glucose-6-phosphate translocator activity leads to increased de novo
lipogenesis and development of hepatic steatosis without affecting
VLDL production in rats. Diabetes 50:2591–2597
Bandsma RHJ, Prinsen BH, de Sain-van d, Velden M et al (2008)
Increased de novo Lipogenesis and delayed conversion of large
VLDL into intermediate density lipoprotein particles contribute to
Hyperlipidemia in glycogen storage disease type 1a. Pediatr Res 63:
702–707. https://doi.org/10.1203/PDR.0b013e31816c9013
Bandsma RHJ, Rake J-P, Visser G et al (2002) Increased lipogenesis and
resistance of lipoproteins to oxidative modification in two patients
with glycogen storage disease type 1a. J Pediatr 140:256–260.
https://doi.org/10.1067/mpd.2002.121382
Besten den G, Havinga R, Bleeker A et al (2014) The short-chain fatty
acid uptake fluxes by mice on a guar gum supplemented diet asso-
ciate with amelioration of major biomarkers of the metabolic syn-
drome. PLoS One 9:e107392. https://doi.org/10.1371/journal.pone.
0107392
Bian F, Kasumov T, Thomas KR et al (2005) Peroxisomal and mitochon-
drial oxidation of fatty acids in the heart, assessed from the 13C
labeling of malonyl-CoA and the acetyl moiety of citrate. J Biol
Chem 280:9265–9271. https://doi.org/10.1074/jbc.M412850200
Bonnefont J-P, Bastin J, Behin A, Djouadi F (2009) Bezafibrate for an
inborn mitochondrial beta-oxidation defect. N Engl J Med 360:838–
840. https://doi.org/10.1056/NEJMc0806334
Bougneres PF, Balasse EO, Ferre P, Bier DM (1986) Determination of
ketone body kinetics using a D-(−)-3-hydroxy[4,4,4-2H3]butyrate
tracer. J Lipid Res 27:215–220
Bougneres PF, Ferre P (1987) Study of ketone body kinetics in children
by a combined perfusion of 13C and 2H3 tracers. Am J Phys 253:
E496–E502
Brosnan JT, BrosnanME, Charron R, Nissim I (1996) Amass isotopomer
study of urea and glutamine synthesis from 15N-labeled ammonia in
the perfused rat liver. J Biol Chem 271:16199–16207
Brosnan JT, Brosnan ME, Nissim I (2004) A window into cellular me-
tabolism: hepatic metabolism of (15)N-labelled substrates. Metab
Eng 6:6–11. https://doi.org/10.1016/j.ymben.2003.10.006
Buescher JM, Antoniewicz MR, Boros LG et al (2015) A roadmap for
interpreting (13)C metabolite labeling patterns from cells. Curr Opin
Biotechnol 34:189–201. https://doi.org/10.1016/j.copbio.2015.02.
003
Catalina-Rodriguez O, Kolukula VK, Tomita Y et al (2012) The mito-
chondrial citrate transporter, CIC, is essential for mitochondrial ho-
meostasis. Oncotarget 3:1220–1235. https://doi.org/10.18632/
oncotarget.714
Clayton TA (2012) Metabolic differences underlying two distinct rat uri-
nary phenotypes, a suggested role for gut microbial metabolism of
phenylalanine and a possible connection to autism. FEBS Lett 586:
956–961. https://doi.org/10.1016/j.febslet.2012.01.049
DeBerardinis RJ, Thompson CB (2012) Cellular metabolism and disease:
what do metabolic outliers teach us? Cell 148:1132–1144. https://
doi.org/10.1016/j.cell.2012.02.032
Derks TGJ, Boer TS, van Assen A et al (2008a) Neonatal screening for
medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in
The Netherlands: the importance of enzyme analysis to ascertain
true MCAD deficiency. J Inherit Metab Dis 31:88–96. https://doi.
org/10.1007/s10545-007-0492-3
Derks TGJ, van Dijk TH, Grefhorst A et al (2008b) Inhibition of mito-
chondrial fatty acid oxidation in vivo only slightly suppresses glu-
coneogenesis but enhances clearance of glucose in mice.
Hepatology 47:1032–1042. https://doi.org/10.1002/hep.22101
Erez A, DeBerardinis RJ (2015) Metabolic dysregulation in monogenic
disorders and cancer-finding method in madness. Nat Rev Cancer
15:440–448. https://doi.org/10.1038/nrc3949
Fletcher JM, Pitt JJ (2001) Fasting medium chain acyl-coenzyme a
dehydrogenase–deficient children can make ketones. Metab Clin
Exp 50:161–165. https://doi.org/10.1053/meta.2001.20177
Gobin-Limballe S, Djouadi F, Aubey F et al (2007) Genetic basis for
correction of very-long-chain acyl-coenzyme a dehydrogenase defi-
ciency by bezafibrate in patient fibroblasts: toward a genotype-based
J Inherit Metab Dis (2018) 41:309–328 325
therapy. Am J Hum Genet 81:1133–1143. https://doi.org/10.1086/
522375
Grefhorst A, Schreurs M, Oosterveer MH et al (2010) Carbohydrate-
response-element-binding protein (ChREBP) and not the liver X
receptor α (LXRα) mediates elevated hepatic lipogenic gene ex-
pression in a mouse model of glycogen storage disease type 1.
Biochem J 432:249–254. https://doi.org/10.1042/BJ20101225
Hakvoort TBM, He Y, Kulik W et al (2017) Pivotal role of glutamine
Synthetase in ammonia detoxification. Hepatology 65:281–293.
https://doi.org/10.1002/hep.2885
Hall AB, Tolonen AC, Xavier RJ (2017) Human genetic variation and the
gut microbiome in disease. Nat Rev Genet 18:690–699. doi: https://
doi.org/10.1038/nrg.2017.63
He Y, Hakvoort TBM, Kohler SE et al (2010) Glutamine Synthetase in
muscle is required for glutamine production during fasting and
Extrahepatic ammonia detoxification. J Biol Chem 285:9516–
9524. https://doi.org/10.1074/jbc.M109.092429
Heales SJ, Thompson GN, Massoud AF et al (1994) Production and
disposal of medium-chain fatty acids in children with medium-
chain Acyl-CoA Dehydrogenase deficiency. J Inherit Metab Dis
17:74–80
HellersteinMK, Neese RA (1992)Mass isotopomer distribution analysis:
a technique for measuring biosynthesis and turnover of polymers.
Am J Phys 263:E988–1001
Hellerstein MK, Neese RA, Linfoot P et al (1997) Hepatic gluconeogenic
fluxes and glycogen turnover during fasting in humans. A stable
isotope study. J Clin Invest 100:1305–1319. https://doi.org/10.
1172/JCI119644
Herrema H, Derks TGJ, van Dijk TH et al (2008) Disturbed hepatic
carbohydrate management during high metabolic demand in
medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice.
Hepatology 47:1894–1904. https://doi.org/10.1002/hep.22284
Hijmans BS, Boss A, van Dijk TH et al (2017) Hepatocytes contribute to
residual glucose production in a mouse model for glycogen storage
disease type Ia. Hepatology 66:2042–2054. https://doi.org/10.1002/
hep.29389
Hiller K, Wegner A, Weindl D et al (2013) NTFD–a stand-alone appli-
cation for the non-targeted detection of stable isotope-labeled com-
pounds in GC/MS data. Bioinformatics 29:1226–1228. https://doi.
org/10.1093/bioinformatics/btt119
Houten SM, Herrema H, Brinke Te H et al (2013) Impaired amino acid
metabolism contributes to fasting-induced hypoglycemia in fatty
acid oxidation defects. Hum Mol Genet 22:5249–5261. https://doi.
org/10.1093/hmg/ddt382
Huidekoper HH, Visser G, Ackermans MT et al (2010) A potential role
for muscle in glucose homeostasis: in vivo kinetic studies in glyco-
gen storage disease type 1a and fructose-1,6-bisphosphatase defi-
ciency. J Inherit Metab Dis 33:25–31. https://doi.org/10.1007/
s10545-009-9030-9
JainM, Nilsson R, SS S et al (2012)Metabolite profiling indentifies a key
role for Glycine in rapid cancer cell proliferation. Science 336:
1040–1044. https://doi.org/10.1107/S0907444911001314
Jiang L, Boufersaoui A, Yang C et al (2016) Metabolic engineering.
Metab Eng 43:198–207. https://doi.org/10.1016/j.ymben.2016.11.
004
Jiang S, Wells CD, Roach PJ (2011) Starch-binding domain-containing
protein 1 (Stbd1) and glycogen metabolism: identification of the
Atg8 family interacting motif (AIM) in Stbd1 required for interac-
tion wirg GABARAPL1. BiochemBiophys Res Commun 413:420–
425. https://doi.org/10.1016/j.bbrc.2011.08.106
Jin Z, Bian F, Tomcik K et al (2015) Compartmentation of metabolism of
the C12-, C9-, and C5-n-dicarboxylates in rat liver, investigated by
mass Isotopomer analysis. J Biol Chem 290:18671–18677
Jones JG, Garcia P, Barosa C et al (2009) Hepatic anaplerotic outflow
fluxes are redirected from gluconeogenesis to lactate synthesis in
patients with type 1a glycogen storage disease. Metab Eng 11:
155–162. https://doi.org/10.1016/j.ymben.2009.01.003
Kalderon B, Korman SH, Gutman A, Lapidot A (1989a) Estimation of
glucose carbon recycling in children with glycogen storage disease:
a 13CNMR study using [U-13C] glucose. Proc Natl Acad Sci U S A
86:4690–4694
Kalderon B, Korman SH, Gutman A, Lapidot A (1989b) Glucose
recycling and production in glycogenosis type Iand III: stable iso-
tope technique study. Am J Physiol Endocrinol Metab 257:E346–
E353
Kalderon B, Lapidot A, Korman SH, Gutman A (1988) Glucose
recycling and production in children with glycogen storage disease
type I, studied by gas chromatography/mass spectrometry and
(U-13C)glucose. Biomed Environ Mass Spectrom 16:305–308
Kalivianakis M, Verkade HJ, Stellaard F et al (1997) The 13C-mixed
triglyceride breath test in healthy adults: determinants of the
13CO2 response. Eur J Clin Investig 27:434–442
Kasumov T, Adams JE, Bian F et al (2005) Probing peroxisomal beta-
oxidation and the labelling of acetyl-CoA proxies with [1-
(13C)]octanoate and [3-(13C)]octanoate in the perfused rat liver.
Biochem J 389:397–401. https://doi.org/10.1042/BJ20050144
Kelleher JK, Kharroubi AT, Aldaghlas TA et al (1994) Isotopomer spec-
tral analysis of cholesterol synthesis: applications in human hepato-
ma cells. Am J Phys 266:E384–E395
Kelleher JK, Masterson TM (1992) Model equations for condensation
biosynthesis using stable isotopes and radioisotopes. Am J Phys
262:E118–E125
Kelleher JK, Nickol GB (2015) Isotopomer spectral analysis: utilizing
nonlinear models in isotopic flux studies. Methods Enzymol 561:
303-30. doi: 10.1016/bs.mie.2015.06.039.
Kolukula VK, Sahu G, Wellstein A et al (2014) SLC25A1, or CIC, is a
novel transcriptional target of mutant p53 and a negative tumor
prognostic marker. Oncotarget 5:1212–1225. https://doi.org/10.
18632/oncotarget.1831
KormanikK, KangH, Cuebas D et al (2012) Evidence for involvement of
medium chain acyl-CoA dehydrogenase in the metabolism of
phenylbutyrate. Mol Genet Metab 107:684–689. https://doi.org/10.
1016/j.ymgme.2012.10.009
Lee B, Hong Y, Jahoor F et al (2000) In vivo urea cycle flux distinguishes
and correlates with phenotypic severity in disorders of the urea cy-
cle. Proc Natl Acad Sci U S A 97:8021–8026. https://doi.org/10.
1073/pnas.140082197
Lei KJ, Chen H, Pan CJ et al (1996) Glucose-6-phosphatase dependent
substrate transport in the glycogen storage disease type-1a mouse.
Nat Genet 13:203–209. https://doi.org/10.1038/ng0696-203
Lenzen S (2014) A fresh view of glycolysis and glucokinase regulation:
history and current status. J Biol Chem 289:12189–12194. https://
doi.org/10.1074/jbc.R114.557314
Leslie ND, Yager KL, McNamara PD, Segal S (1996) A mouse model of
galactose-1-phosphate Uridyl Transferase deficiency. Biochem Mol
Med 59:7–12
Marini JC, Lee B, Garlick PJ (2006a) Reduced ornithine
transcarbamylase activity does not impair ureagenesis in Otcspf-ash
mice. J Nutr 136:1017–1020
Marini JC, Lee B, Garlick PJ (2006b) Ornithine restores ureagenesis
capacity and mitigates hyperammonemia in Otcspf-ash mice. J Nutr
136:1834–1838
Martines A-CMF, van Eunen K, Reijngoud D-J, Bakker BM (2017) The
promiscuous enzyme medium-chain 3-keto-acyl-CoA thiolase trig-
gers a vicious cycle in fatty-acid beta-oxidation. PLoS Comput Biol
13:e1005461. https://doi.org/10.1371/journal.pcbi.1005461
Matini JC, Lee B, Garlick PJ (2005) In vivo urea kinetics studies in
conscious mice. J Nutr 136:202–206
Matthews DE, Downey RS (1984) Measurement of urea kinetics in
humans: a validation of stable isotope tracer methods. Am J Phys
246:E519–E527
326 J Inherit Metab Dis (2018) 41:309–328
Meija J, Coplen TB, BerglundM et al (2016) Isotopic compositions of the
elements 2013 IUPAC technical report. Pure Appl Chem 88:131.
https://doi.org/10.1016/j.ijms.2005.06.006
Metallo CM, Gameiro PA, Bell EL et al (2011) Reductive glutamine
metabolism by IDH1 mediates lipogenesis under hypoxia. Nature
481:380–384. https://doi.org/10.1038/nature10602
Midani FS, Wynn ML, Schnell S (2017) The importance of accurately
correcting for the natural abundance of stable isotopes. Anal
Biochem 520:27–43. https://doi.org/10.1016/j.ab.2016.12.011
Mullen AR, Wheaton WW, Jin ES et al (2011) Reductive carboxylation
supports growth in tumour cells with defective mitochondria. Nature
481:385–388. https://doi.org/10.1038/nature10642
Mutel E, Abdul-Wahed A, Ramamonjisoa N et al (2011) Targeted dele-
tion of liver glucose-6 phosphatase mimics glycogen storage disease
type 1a including development of multiple adenomas. J Hepatol 54:
529–537. https://doi.org/10.1016/j.jhep.2010.08.014
Nissim I, Brosnan ME, Yudkoff M, Brosnan JT (1999) Studies of hepatic
glutamine metabolism in the perfused rat liver with (15)N-labeled
glutamine. J Biol Chem 274:28958–28965
Nissim I, Cattano C, Nissim I, Yudkoff M (1992) Relative role of the
glutaminase, glutamate dehydrogenase, and AMP-deaminase path-
ways in hepatic ureagenesis: studies with 15N. Arch Biochem
Biophys 292:393–401
Nissim I, Horyn O, Luhovyy B et al (2003) Role of the glutamate dehy-
drogenase reaction in furnishing aspartate nitrogen for urea synthe-
sis: studies in perfused rat liver with 15N. Biochem J 376:179–188.
https://doi.org/10.1042/BJ20030997
Nissim I, Yudkoff M, Brosnan JT (1996) Regulation of [15N]urea syn-
thesis from [5-15N]glutamine. Role of pH, hormones, and pyruvate.
J Biol Chem 271:31234–31242
Nota B, Struys EA, Pop A et al (2013) Deficiency in SLC25A1, encoding
the mitochondrial citrate carrier, causes combined D-2- and L-2-
hydroxyglutaric aciduria. Am J Hum Genet 92:627–631. https://
doi.org/10.1016/j.ajhg.2013.03.009
Oosterveer MH, Grefhorst A, van Dijk TH et al (2009) Fenofibrate si-
multaneously induces hepatic fatty acid oxidation, synthesis, and
elongation in mice. J Biol Chem 284:34036–34044. https://doi.
org/10.1074/jbc.M109.051052
Posset R, Opp S, Struys EA et al (2014) Understanding cerebral L-lysine
metabolism: the role of L-pipecolate metabolism in Gcdh-deficient
mice as a model for glutaric aciduria type I. J Inherit Metab Dis 38:
265–272. https://doi.org/10.1016/0014-4827(86)90475-1
Powell RC, Wentworth SM, Brandt IK (1981) Endogenous glucose pro-
duction in type I glycogen storage disease. Metabolism 30:443–450
Ramoni RB, Mulvihill JJ, Adams DR et al (2017) The undiagnosed
diseases network: accelerating discovery about health and disease.
Am JHumGenet 100:185–192. https://doi.org/10.1016/j.ajhg.2017.
01.006
Reijngoud D-J, Verkade HJ (2017) Applications in fat absorption and
metabolism. In: Schierbeek H (ed) Mass spectrometry and stable
isotopes in nutritional and pediatric research, 1st edn. John Wiley
and Sons, Hoboken, pp 175–212
Reszko AE, Kasumov T, David F et al (2004) Peroxisomal fatty acid
oxidation is a substantial source of the acetyl moiety of malonyl-
CoA in rat heart. J Biol Chem 279:19574–19579. https://doi.org/10.
1074/jbc.M400162200
Richards P, Ourabah S, Montagne J et al (2017) MondoA/ChREBP: the
usual suspects of transcriptional glucose sensing; implication in
pathophysiology. Metab Clin Exp 70:133–151. https://doi.org/10.
1016/j.metabol.2017.01.033
Rinaldo P, O'Shea JJ, Welch RD, Tanaka K (1990) The enzymatic basis
for the dehydrogenation of 3-phenylpropionic acid: in vitro reaction
of 3-phenylpropionyl-CoAwith various acyl-CoA dehydrogenases.
Pediatr Res 27:501–507. https://doi.org/10.1203/00006450-
199005000-00017
Rother KI, Schwenk F (1995) Glucose production in glycogen storage
disease I is not associated with increased cycling through hepatic
glycogen. Am J Physiol Endocrinol Metab 269:E774–E778
Sahoo S, Franzson L, Jonsson JJ, Thiele I (2012) A compendium of
inborn errors of metabolism mapped onto the human metabolic net-
work. Mol BioSyst 8:2545. https://doi.org/10.1093/nar/gkm882
Scaglia F, Marini JC, Rosenberger J et al (2003) Differential utilization of
systemic and enteral ammonia for urea synthesis in control subjects
and ornithine transcarbamylase deficiency carriers. Am J Clin Nutr
78:749–755
Scaglia F, Zheng Q, O'Brien WE et al (2002) An integrated approach to
the diagnosis and prospective management of partial ornithine
transcarbamylase deficiency. Pediatrics 109:150–152
Shlomi T, Cabili MN, Ruppin E (2009) Predicting metabolic biomarkers
of human inborn errors of metabolism. Mol Syst Biol. 5:263. doi:
https://doi.org/10.1038/msb.2009.22
Struys EA, Jakobs C (2010) Metabolism of lysine in aminoadipic semi-
aldehyde dehydrogenasedeficient fibroblasts: evidence for an alter-
native pathway of pipecolic acid formation. FEBS Lett 584:181–
186. https://doi.org/10.1016/j.febslet.2009.11.055
Taruscio D, Groft SC, Cederroth H et al (2015) Undiagnosed disease
network international (UDNI): white paper for global actions to
meet patient needs. Mol Genet Metab 116:223–225. https://doi.
org/10.1016/j.ymgme.2015.11.003
Thiele I, Swainston N, Fleming RMT et al (2013) A community-driven
global reconstruction of human metabolism. Nat Biotechnol 31:
419–425. https://doi.org/10.1038/nbt.2488
Thompson GN, Halliday D (1990) Significant phenylalanine hydroxyl-
ation in vivo in patients with classical phenylketonuria. J Clin Invest
86:317–322. https://doi.org/10.1172/JCI114701
Thompson GN, Walter JH, Bresson JL et al (1990a) Sources of propio-
nate in inborn errors of propionate metabolism. Metab Clin Exp 39:
1133–1137
Thompson GN, Walter JH, Leonard JV, Halliday D (1990b) In vivo en-
zyme activity in inborn errors of metabolism. Metabolism 39:799–
807
Tolwani RJ, Hamm DA, Tian L et al (2005) Medium-chain acyl-CoA
dehydrogenase deficiency in gene-targeted mice. PLoSGenet 1:e23.
https://doi.org/10.1371/journal.pgen.0010023
Tredwell GD, Keun HC (2015) convISA: a simple, convoluted method
for isotopomer spectral analysis of fatty acids and cholesterol. Metab
Eng 32:125–132. https://doi.org/10.1016/j.ymben.2015.09.008
Tsalikian E, Simmons P, Gerich JE et al (1984) Glucose production and
utilization in childrenwith glycogen storage disease type I. Am J
Physiol Endocrinol Metab 247:E513–E519
van Dijk TH, van der Sluijs FH, Wiegman CH et al (2001) Acute inhibi-
tion of hepatic glucose-6-phosphatase does not affect gluconeogen-
esis but directs gluconeogenic flux toward glycogen in fasted rats. A
pharmacological study with the chlorogenic acid derivative S4048. J
Biol Chem 276:25727–25735. https://doi.org/10.1074/jbc.
M101223200
van Eunen K, Simons SMJ, Gerding A et al (2013) Biochemical compe-
tition makes fatty-acid β-oxidation vulnerable to substrate overload.
PLoS Comput Biol 9:e1003186. https://doi.org/10.1371/journal.
pcbi.1003186.s008
van Eunen K, Volker-Touw CML, Gerding A et al (2016) Living on the
edge: substrate competition explains loss of robustness in mitochon-
drial fatty-acid oxidation disorders. BMC Biol 14:107. https://doi.
org/10.1186/s12915-016-0327-5
van Spronsen FJ, Reijngoud DJ, Smit GP et al (1998) Phenylketonuria.
The in vivo hydroxylation rate of phenylalanine into tyrosine is
decreased. J Clin Invest 101:2875–2880. https://doi.org/10.1172/
JCI737
Vasilakou E, Machado D, Theorell A et al (2016) Current state and chal-
lenges for dynamic metabolic modeling. Curr Opin Microbiol 33:
97–104. https://doi.org/10.1016/j.mib.2016.07.008
J Inherit Metab Dis (2018) 41:309–328 327
Veeneman JM, Kingma HA, Stellaard F et al (2004) Comparison of
amino acid oxidation and urea metabolism in haemodialysis patients
during fasting andmeal intake. NephrologyDialysis Transplantation
19:1533–1541. https://doi.org/10.1093/ndt/gfh236
Veeneman JM, Kingma HA, Stellaard F et al (2005) Oxidative metabo-
lism appears to be reduced in long-term hemodialysis patients. Am J
Kidney Dis 46:102–110
Violante S, Ijlst L, Brinke Te H et al (2013) Peroxisomes contribute to the
acylcarnitine production when the carnitine shuttle is deficient.
Biochim Biophys Acta 1831:1467–1474. https://doi.org/10.1016/j.
bbalip.2013.06.007
Wager K, Mahmood F, Russell C (2014) Modelling inborn errors of
metabolism in zebrafish. J Inherit Metab Dis 37:483–495. https://
doi.org/10.1007/s10545-014-9696-5
Wanders RJA (2014) Metabolic functions of peroxisomes in health and
disease. Biochimie 98:36–44. https://doi.org/10.1016/j.biochi.2013.
08.022
Wanders RJA, Komen J, Kemp S (2010) Fatty acid omega-oxidation as a
rescue pathway for fatty acid oxidation disorders in humans. FEBS J
278:182–194. https://doi.org/10.1111/j.1742-4658.2010.07947.x
Wanders RJA, Waterham HR, Ferdinandusse S (2016) Metabolic inter-
play between peroxisomes and other subcellular organelles includ-
ing mitochondria and the endoplasmic reticulum. Front Cell Dev
Biol 3:1752. https://doi.org/10.1016/0005-2736(87)90321-X
Wangler MF, Yamamoto S, Chao H-T et al (2017) Model organisms
facilitate rare disease diagnosis and therapeutic research. Genetics
207:9–27. https://doi.org/10.1534/genetics.117.203067
Watson E, Olin-Sandoval V, Hoy MJ et al (2016) Metabolic network
rewiring of propionate flux compensates vitamin B12 deficiency
in C. Elegans. elife. https://doi.org/10.7554/eLife.17670
Weghuber D,MandlM, KrssakM et al (2007) Characterization of hepatic
and brain metabolism in young adults with glycogen storage disease
type 1: a magnetic resonance spectroscopy study. Am J Physiol
Endocrinol Metab 293:E1378–E1384. https://doi.org/10.1152/
ajpendo.00658.2006
Weindl D, Wegner A, Hiller K (2016) MIA: non-targeted mass
isotopolome analysis. Bioinformatics 32:2875–2876. https://doi.
org/10.1093/bioinformatics/btw317
Wellen KE, Hatzivassiliou G, Sachdeva UM et al (2009) ATP-citrate
lyase links cellular metabolism to histone acetylation. Science 324:
1076–1080
Wilson KA, Han Y, Zhang M et al (2017) Interrelations between 3-
hydroxypropionate and propionate metabolism in rat liver: rele-
vance to disorders of propionyl-CoA metabolism. Am J Physiol
Endocrinol Metab https://doi.org/10.1152/ajpendo.00105.2017
Wong TL, Che N, Ma S (2017) Reprogramming of central carbon me-
tabolism in cancer stem cells. Biochim Biophys Acta 1863:1728–
1738. https://doi.org/10.1016/j.bbadis.2017.05.012
Xu J, Du Y, Deng H (2015) Direct lineage reprogramming: strategies,
mechanisms, and applications. Cell Stem Cell 16:119–134. https://
doi.org/10.1016/j.stem.2015.01.013
Yang D, Hazey JW, David F et al (2000) Integrative physiology of
splanchnic glutamine and ammonium metabolism. Am J Physiol
Endocrinol Metab 278:E469–E476
Yudkoff M, Daikhin Y, Ye X et al (1998) In vivo measurement of
ureagenesis with stable isotopes. J Inherit Metab Dis 21:21–29
328 J Inherit Metab Dis (2018) 41:309–328
